Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. - Wikidata - awgldk - TriplyDB

Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

http://www.wikidata.org/entity/Q51536797

about

Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.The potential of p38 MAPK inhibitors to modulate periodontal infections.Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells.Use of pharmacokinetic data below lower limit of quantitation values Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase Novel host response therapeutic approaches to treat periodontal diseases.Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.Future therapeutic treatment of COPD: struggle between oxidants and cytokines Targeting lung inflammation: novel therapies for the treatment of COPD.Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.Anticytokine therapy for periodontal diseases: Where are we now?Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines.Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood.Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts.Activation of p38 MAPKalpha by extracellular pressure mediates the stimulation of macrophage phagocytosis by pressure.Interaction of Neisseria meningitidis with human brain microvascular endothelial cells: role of MAP- and tyrosine kinases in invasion and inflammatory cytokine release.Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro.A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model.Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury.

P2860

Q24805749-B52DB570-8C02-4953-82B3-62C4027A00A7 Q33301990-43673DC0-5C48-4304-B525-3E347A653284 Q33606744-E7D13E1E-0412-4F49-8C22-748BB78BBAE9 Q34208163-23E7EAFD-AF8E-49FE-818F-0344DBB2772B Q34315916-62428DBB-1368-49B4-8929-85D31B3A1E4A Q35828722-681B50F0-7FD6-47A4-9978-E3AAB277F41A Q35848170-DC8FD301-0B57-4526-AB84-03E1C2204164 Q36135818-8222EDF0-0E65-496E-9C79-DE6186AA337B Q36703987-FDD32888-93ED-4010-A911-FD25C95D9FDC Q36716750-9C12E61F-0034-4DD0-AA9B-33130DAC2DCF Q37071004-E354E56C-790A-48C8-815B-2D7B66C56E28 Q37578310-2CCB36DB-AFEA-4A16-8BEE-F98ED0BD421E Q38078271-71E0AC2F-BA2E-44DF-B888-97E0F7C33C87 Q38908783-D801748F-3F0B-4654-BFD0-8185B6CD6DB2 Q39841074-8304E6C5-DBFD-4F28-A08C-5363B8FED397 Q40354904-B4B4C8DC-4763-4811-A416-C699AB40A3AD Q41468161-ACC7389F-001F-43C3-A64E-CD664F352BDF Q41879329-6C05C925-FC9E-495A-8267-FD0F322AD52B Q42472385-CE3BBD4D-F850-471B-849E-7FDC5A61EAE2 Q45139978-415E05AF-1F0D-4BD7-B61E-6D31EDD9111F Q46562009-7B03B42D-0BF3-4FE7-9B04-4B8D5A3426F2 Q46864205-22757BAC-4F91-4B4E-9978-65B2FA9E3E89 Q54589616-F8C72DAC-2F55-4087-B1E7-9866C77B18A4

P2860

Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

http://www.wikidata.org/entity/Q51536797

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@en

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@nl

type

label

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@en

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@nl

prefLabel

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@en

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@nl

P1433

Q51536797-F5CC8DE7-600E-49E8-A376-F67060B84AF6

P1476

Q51536797-F3F239FE-F535-4880-BAAA-E3226A5EB8DC

P2093

Q51536797-1666D7BC-7A29-43F3-8157-E5D02744408A

Q51536797-3A241A0A-9739-4487-835C-5AB6E57FAA87

Q51536797-84E4B836-3289-4E61-A015-E06825F8C13B

Q51536797-D22EC46F-60D5-4666-A2A8-9DFCE576279E

Q51536797-FD0B2674-1006-41E9-BCDB-5EC56ECD05E5

P2860

Q51536797-12D03432-6F4D-4082-803C-1EA88B3B9BB8

Q51536797-5469633C-D984-432D-8033-64773AF57A17

Q51536797-5BFAEB98-99D1-43A7-AFB4-5C75D9D823ED

Q51536797-62DE32A2-6EBB-4841-81C8-3C7C4E857AE9

Q51536797-B9EBA62A-FA2C-40E8-9E77-9236FD4E2AE0

Q51536797-C13F3F04-0987-4816-878F-5A94531CFF1D

Q51536797-F48FEC96-5C17-4DB4-9322-50327978FDA6

P304

Q51536797-8169A91F-EFCA-4F05-AEAB-9CA4375431F6

P31

Q51536797-9BD83ED2-9DF4-4523-AE52-8DC1415E94E7

P356

Q51536797-E355A854-5423-4363-94E5-94F7E89B899C

P433

Q51536797-D9054C23-C054-4C61-ACA1-361B2705D816

P478

Q51536797-15182438-6B0E-4562-A936-5E69AC3F0A78

P577

Q51536797-5BF76034-A85C-482D-8D5C-49C6AD8764B9

P698

Q51536797-7CF64117-963B-4EEA-97CF-823BFF794FFB

P356

0091270002250615

P1433

The Journal of Clinical Pharmacology

P1476

Single-dose pharmacokinetics a ...... bitor: a first-in-human study.

@en

P2093

Andrew T Chow

http://www.w3.org/2001/XMLSchema#string

C Richard Jones

http://www.w3.org/2001/XMLSchema#string

Daksha Desai-Krieger

http://www.w3.org/2001/XMLSchema#string

Dolly A Parasrampuria

http://www.w3.org/2001/XMLSchema#string

Peter de Boer

http://www.w3.org/2001/XMLSchema#string

P2860

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression

Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.

The Win1 mitotic regulator is a component of the fission yeast stress-activated Sty1 MAPK pathway.

Regulation of the proinflammatory effects of Fas ligand (CD95L).

Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.

The neuronal death induced by endotoxic shock but not that induced by excitatory amino acids requires TNF-alpha.

P304

406-413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270002250615

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12723461

http://www.w3.org/2001/XMLSchema#string